Fiscal impact of a potential legislative ban on second trimester elective terminations for prenatally diagnosed abnormalities

Am J Med Genet. 2000 Apr 24;91(5):359-62.

Abstract

This study was designed to determine the fiscal impact of a theoretical legislative ban on elective terminations for prenatally diagnosed abnormalities at Hutzel Hospital/Wayne State University. A fiscal comparison was completed for patients who had second trimester elective terminations for prenatally diagnosed abnormalities versus not allowing the procedure. An eight-year database of genetics cases and hospital and physician cost estimates for performing elective terminations for prenatally diagnosed abnormalities, and published reports of the average lifetime costs per selected birth defects, were used to calculate the net cost. The estimated lifetime cost for an average cohort year of a legislative ban on elective terminations for prenatally diagnosed abnormalities was found to be at least $8.5 million for patients treated at Hutzel Hospital. Extrapolated, a similar ban on second trimester elective terminations would have a net cost of $74 million in Michigan and $2 billion annually in the United States.

MeSH terms

  • Abortion, Induced* / economics
  • Congenital Abnormalities / diagnosis
  • Congenital Abnormalities / economics*
  • Congenital Abnormalities / genetics
  • Cost of Illness
  • Female
  • Humans
  • Legislation, Medical / economics*
  • Michigan
  • Pregnancy
  • Pregnancy Trimester, Second
  • Prenatal Diagnosis*
  • United States